This clinical trial is focused on studying Non-Small Cell Lung Cancer (NSCLC), a common type of lung cancer. The study will compare two treatments: SGN-B6A and docetaxel. SGN-B6A is a new treatment that involves a special type of protein called a monoclonal antibody, which is designed to target cancer cells. It is combined with a drug that helps kill these cells. Docetaxel is a chemotherapy medication that is already used to treat various cancers, including lung cancer.
The purpose of the study is to see which treatment is more effective for patients who have already received treatment for their lung cancer. Participants will be randomly assigned to receive either SGN-B6A or docetaxel. The study will monitor how well each treatment works in terms of overall survival and response to the treatment. This means researchers will look at how long patients live and how their cancer responds to the treatment.
Throughout the study, participants will receive their assigned treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to 60 days, during which time participants will be closely monitored by the research team. The goal is to gather information that could help improve treatment options for people with Non-Small Cell Lung Cancer.
Austria 
Belgium 
Czechia 
France 
Germany 
Greece 
Hungary 
Italy 
Norway 
Poland 
Romania 
Spain 
The Netherlands 